U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07077512) titled 'Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma' on July 01.
Brief Summary: This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of Relmacabtagene Autoleucel in combination with the Sintilimab regimen for the treatment of relapsed/refractory B-cell lymphoma
Study Start Date: July 15
Study Type: INTERVENTIONAL
Condition:
Large B Cell Diffuse Lymphoma
Mantle Cell Lymphoma (MCL)
Follicular Lymphoma ( FL)
Intervention:
DRUG: Autoleucel (Relmacabtagene Autoleucel)
Relmacabtagene Autoleucel will be reinfused 2 to 7 days after lymphodep...